Bio-IT World September 26, 2024
ArsenalBio plans to advance their lead programs through development invests in candidates for solid tumor cancers based on its proprietary T cell engineering technology; eGenesis moves to a first-in-human study for kidney transplant; SpectraWAVE will advance commercial expansion and product additions to their 510k-cleared HyperVue Imaging System; and more.
$390M: Series A for T-Cell Engager Antibodies
Candid Therapeutics debuted with a $370 million capital raise for its T-cell engager (“TCE”) antibodies that can deplete specific B lymphocyte cell populations. B lymphocytes lead to autoimmune pathology by producing autoantibodies that attack the body’s own tissues and through antigen presentation and cytokine release. Selective depletion of B lymphocytes has shown unprecedented clinical efficacy in highly refractory patients...
Today's Sponsors
Today's Sponsor